footandmouth
diseas
fmd
econom
signific
anim
diseas
speed
transmiss
current
fmd
vaccin
provid
protect
day
vaccin
reduc
effect
case
outbreak
therefor
find
altern
method
appli
antivir
agent
rapid
enhanc
inhibit
fmd
viru
fmdv
compar
antivir
effect
promis
antivir
agent
attempt
appli
combin
first
measur
compar
effect
concentr
ec
mean
inhibit
effect
fmdv
cytotox
concentr
cc
mean
cytotox
antivir
agent
ribavirin
guanidinehydrochlorid
guanidinehcl
recombin
adenoviru
express
three
small
interfer
rna
adsirna
porcin
interferona
adporcin
ifna
swine
kidney
cell
select
indic
ribavirin
higher
guanidinehcl
select
indic
adsirna
adporcin
ifna
base
adenovir
titer
next
test
combin
effect
fmdv
inhibit
agent
enhanc
inhibit
effect
observ
cell
suckl
mice
combin
adporcin
ifna
adsirna
ribavirin
combin
applic
recombin
adenovirus
ribavirin
may
enhanc
inhibitori
effect
fmdv
overcom
fmdv
resist
antivir
agent
abbrevi
cpe
cytopath
effect
cytotox
concentr
requir
reduc
cell
viabil
effect
concentr
requir
reduc
virusinduc
cytopathogen
fmd
footandmouth
diseas
fmdv
footandmouth
diseas
viru
guanidinehcl
guanidin
hydrochlorid
ifn
interferon
ip
intraperiton
sd
standard
deviat
sirna
small
interfer
rna
shrna
short
hairpin
rna
rnai
rna
interfer
rtpcr
revers
transcriptas
polymeras
chain
reaction
tcid
tissu
cultur
infect
dose
dpc
day
post
challeng
pi
post
infect
ld
lethal
dose
footandmouth
diseas
fmd
highli
contagi
diseas
affect
clovenhoof
anim
cattl
swine
sheep
pereira
abil
fmd
viru
fmdv
spread
rapidli
suscept
anim
led
fmd
consid
diseas
seriou
enough
list
world
organ
anim
health
oie
fmdv
belong
genu
aphthoviru
famili
picornavirida
bachrach
viru
genom
positivesens
singlestrand
rna
contain
one
open
read
frame
serotyp
c
moreov
numer
subtyp
evolv
within
serotyp
knowl
samuel
domingo
et
al
use
current
fmd
vaccin
induc
earli
protect
limit
protect
take
effect
day
vaccin
gold
et
al
therefor
altern
method
appli
antivir
agent
requir
reduc
spread
fmdv
outbreak
situat
guanidinehydrochlorid
guanidinehcl
ribavirin
interferon
ifn
small
interfer
rna
sirna
propos
promis
antivir
agent
differ
mechan
howev
inhibit
effect
fmdv
evalu
although
differ
antivir
effici
furthermor
treatment
individu
antivir
agent
lead
perfect
inhibit
limit
relat
viral
resist
ribavirin
guanidinehcl
known
chemic
compound
inhibit
fmdv
replic
cell
nettleton
et
al
guanidinehcl
inhibit
replic
picornavirus
fmdv
polioviru
ribavirin
antivir
effect
broad
rang
virus
includ
fmdv
inhibit
rnacap
activ
viral
polymeras
increas
mutat
frequenc
graci
cameron
broadspectrum
antimetabolit
inhibit
viru
replic
rada
dragun
report
effect
inhibit
rna
virus
chikungunya
viru
semliki
forest
viru
human
coronaviru
low
concentr
briolant
et
al
pyrc
et
al
howev
report
whether
effect
inhibit
fmdv
recombin
adenoviru
express
porcin
ifna
induc
high
level
biolog
activ
ifn
cell
supernat
antivir
effect
fmdv
cell
protect
last
day
swine
inocul
adenoviru
chinsangaram
et
al
rna
interfer
rnai
caus
gene
silenc
sequencespecif
manner
mediat
short
hairpin
rna
recent
research
report
inhibit
fmdv
replic
use
plasmid
adenoviru
express
rnai
chen
et
al
chen
et
al
kahana
et
al
report
signific
antivir
effect
fmdv
adenoviru
express
multipl
sirna
target
nonstructur
protein
gene
kim
et
al
multipl
sirna
enhanc
antivir
effici
antivir
effect
fmdv
serotyp
howev
fmdv
possess
resist
mechan
antivir
agent
amino
acid
substitut
mutagen
mutat
sirna
target
sequenc
type
ifn
suppress
belsham
normann
de
la
torr
et
al
parient
et
al
pfister
wimmer
pusch
et
al
group
anticip
combin
treatment
antivir
agent
differ
mechan
might
advantag
overcom
individu
limit
moreov
fmd
research
report
combin
treatment
type
ii
ifn
guanidinehcl
ribavirin
enhanc
antivir
effect
mora
et
al
peral
et
al
examin
compar
inhibit
effect
cytotox
follow
wellknown
potenti
antivir
agent
guanidinehcl
ribavirin
recombin
adenoviru
express
porcin
ifna
adporcin
ifna
multipl
sirna
adsirna
previou
studi
kim
et
al
adsirna
studi
furthermor
test
combin
effect
four
pair
mix
antivir
agent
select
follow
five
agent
guanidinehcl
ribavirin
adporcin
ifna
adsirna
first
time
enhanc
antivir
effect
combin
adporcin
ifna
adsirna
adporcin
ifna
ribavirin
demonstr
human
embryon
kidney
cell
includ
contain
human
adenoviru
type
dna
cell
swine
kidney
cell
propag
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
ph
antibiot
co
icr
suckl
mice
day
old
weigh
g
purchas
orient
co
ltd
republ
korea
anim
treat
accord
ethic
guidelin
anim
welfar
committe
anim
plant
fisheri
quarantin
inspect
agenc
qia
fmdv
strain
genbank
access
number
use
viral
challeng
viru
titer
fmdv
adenoviru
determin
cell
respect
tissu
cultur
infect
dose
tcid
calcul
use
formula
reed
muench
reed
muench
purchas
commerci
chemic
compound
ribavirin
sigma
usa
guanidinehcl
thermo
scientif
usa
sigma
aldrich
usa
produc
recombin
adenovirus
adsirna
adporcin
ifna
laboratori
ribavirin
guanidinehcl
report
applic
case
fmdv
black
brown
de
la
torr
et
al
report
previous
recombin
adenoviru
express
three
differ
sirna
sequenc
target
nonstructur
protein
region
adsirna
significantli
inhibit
fmdv
replic
kim
et
al
produc
adporcin
ifna
porcin
gene
genbank
access
number
synthes
bioneer
corp
republ
korea
clone
clone
vector
invitrogen
usa
recombin
human
adenoviru
produc
accord
manufactur
instruct
briefli
perform
recombin
reaction
use
construct
invitrogen
gateway
vector
invitrogen
gateway
lr
enzym
mix
invitrogen
cell
transfect
adenoviru
construct
digest
paci
use
lipofectamin
invitrogen
approxim
cytopath
effect
cpe
observ
adenoviru
harvest
harvest
viru
purifi
use
virabind
adenoviru
miniprep
kit
cell
biolab
inc
usa
adenoviru
stock
tcid
ml
use
experi
inhibit
effect
cytotox
measur
cell
compar
effect
antivir
agent
fmdv
cell
per
well
plate
plate
follow
day
plate
cell
confluent
time
infect
cell
infect
tcid
fmdv
treat
recombin
adenovirus
serial
dilut
chemic
compound
h
postfmdv
infect
cell
incub
h
maximum
cpe
fmdv
reach
level
viabil
infect
cell
determin
mt
assay
use
celltit
aqueou
one
solut
prolifer
assay
promega
usa
antivir
activ
express
effect
concentr
ec
defin
concentr
requir
reduc
virusinduc
cytopathogen
control
valu
similar
procedur
use
cytotox
assay
cell
treat
recombin
adenovirus
chemic
compound
without
fmdv
infect
cytotox
determin
mt
assay
use
celltit
aqueou
one
solut
prolifer
assay
promega
cytotox
express
cytotox
concentr
cc
defin
concentr
requir
reduc
cell
viabil
control
valu
investig
antivir
effect
antivir
agent
combin
vitro
cell
inocul
plate
cell
inocul
recombin
adenoviru
express
porcin
ifna
sirna
ribavirin
guanidinehcl
combin
two
antivir
agent
h
fmdv
infect
experi
illustr
fig
adsirna
adporcin
ifna
ribavirin
treatment
carri
h
fmdv
infect
depict
fig
experi
illustr
fig
adporcin
ifna
ribavirin
treatment
carri
h
fmdv
infect
simultan
treatment
experi
adporcin
ifna
ribavirin
ad
h
respect
fmdv
infect
sequenti
treatment
experi
adenoviru
chemic
compound
remov
cell
wash
twice
dmem
cell
immedi
infect
tcid
fmdv
absorpt
inocula
remov
cultur
medium
contain
fb
ad
experi
depict
fig
inocula
remov
experi
depict
fig
cell
incub
h
supernat
collect
h
postinfect
pi
analyz
replic
analysi
quantit
realtim
rtpcr
carri
assay
effect
antivir
agent
fmdv
rna
replic
viral
rna
extract
magna
pure
lc
system
roch
switzerland
realtim
rtpcr
conduct
describ
previous
kim
et
al
ttest
perform
statist
analysi
use
graph
pad
instat
ver
use
suckl
mice
investig
antivir
effect
vivo
studi
fmdv
dose
determin
serial
dilut
viru
lethal
dose
ld
fmdv
use
estim
reedmuench
method
reed
muench
suckl
mice
inocul
intraperiton
ip
inject
mg
ribavirin
tcid
adenoviru
combin
group
treat
adporcin
ifna
adsirna
inject
tcid
adenoviru
h
combin
group
treat
ribavirin
adporcin
ifna
sequenti
treatment
inject
mg
ribavirin
h
adenoviru
ribavirin
inject
suckl
mice
challeng
ld
ld
fmdv
oskr
ip
inject
anim
monitor
day
log
rank
test
perform
statist
analysi
use
graph
pad
instat
ver
inhibit
effect
antivir
agent
determin
inhibit
fmdvinduc
cpe
cytotox
antivir
agent
determin
viabil
treat
cell
select
indic
effect
antivir
agent
calcul
ratio
cc
ec
agent
demonstr
select
indic
fmdv
tabl
regard
chemic
compound
ribavirin
select
indic
respect
higher
guanidinehcl
select
index
select
index
whose
effect
fmdv
unknown
point
similar
ribavirin
ribavirin
prove
select
fmdv
inhibitor
guanidinehcl
lowest
select
index
chemic
compound
examin
studi
select
indic
adenovirus
express
sirna
porcin
ifna
base
adenovir
titer
cell
select
index
porcin
ifna
higher
sirna
determin
combin
antivir
agent
greater
antivir
effect
individu
agent
fmdv
replic
cell
analyz
combin
individu
treatment
fig
antivir
agent
exhibit
statist
signific
inhibit
fmdv
replic
compar
control
p
ttest
antivir
effect
combin
treatment
use
ribavirin
lm
adporcin
ifna
tcid
enhanc
treatment
use
ribavirin
p
ttest
adporcin
ifna
p
ttest
alon
h
pi
fig
addit
antivir
effect
combin
treatment
use
adsirna
tcid
adporcin
ifna
tcid
enhanc
treatment
use
adsirna
p
ttest
adporcin
ifna
p
ttest
alon
h
pi
fig
howev
inhibit
effect
due
combin
treatment
use
ribavirin
lm
lm
lower
due
treatment
alon
although
inhibit
effect
combin
treatment
higher
use
ribavirin
alon
p
ttest
fig
antivir
effect
combin
adporcin
ifna
lm
similar
sole
treatment
fig
ribavirin
adporcin
ifna
help
antifmdv
effect
also
examin
effect
tcid
adporcin
ifna
combin
variou
amount
titer
ribavirin
adsirna
fmdv
replic
fig
combin
tcid
adporcin
ifna
titer
adsirna
improv
antivir
effect
individu
adporcin
ifna
treatment
p
fig
inhibit
effect
proport
adsirna
titer
combin
featur
tcid
adporcin
ifna
particular
combin
tcid
adporcin
ifna
tcid
adsirna
enhanc
inhibit
effect
viral
copi
number
approxim
compar
treatment
tcid
adporcin
ifna
alon
combin
adporcin
ifna
titer
greater
tcid
adsirna
enhanc
inhibit
effect
viral
copi
number
approxim
compar
treatment
adporcin
ifna
alon
combin
tcid
adporcin
ifna
adsirna
exhibit
similar
antivir
effect
combin
tcid
adporcin
ifna
ribavirin
concentr
except
lm
ribavirin
improv
antivir
effect
treatment
tcid
adporcin
ifna
p
fig
combin
adporcin
ifna
lm
lm
ribavirin
enhanc
inhibit
effect
viral
copi
number
approxim
compar
treatment
adporcin
ifna
alon
moreov
combin
adporcin
ifna
lm
lm
ribavirin
enhanc
inhibit
effect
viral
copi
number
approxim
compar
treatment
adporcin
ifna
alon
howev
combin
tcid
adporcin
ifna
concentr
ribavirin
except
lm
ribavirin
improv
antivir
effect
compar
treatment
tcid
adporcin
ifna
p
investig
quickli
antivir
effect
induc
compar
inhibit
effect
adsirna
adporcin
ifna
ribavirin
administ
variou
interv
fmdv
infect
h
fig
h
fmdv
infect
adsirna
adporcin
ifna
decreas
fmdv
copi
number
adenoviru
treatment
group
log
howev
statist
signific
differ
antivir
effect
ribavirin
adenovirus
ribavirin
signific
antivir
effect
p
adsirna
effect
adporcin
ifna
initi
stage
treatment
h
fmdv
infect
p
moreov
antivir
effect
adenovirus
superior
ribavirin
though
antivir
effect
ribavirin
improv
compar
h
infect
h
fmdv
infect
adsirna
adporcin
ifna
ribavirin
treatment
demonstr
consider
antivir
effect
similar
level
statist
signific
p
adsirna
adporcin
ifna
took
effect
quickli
ribavirin
though
inhibit
effect
agent
depend
incub
period
h
compar
antivir
effect
simultan
treatment
administ
mixtur
adporcin
ifna
ribavirin
sequenti
treatment
adporcin
ifna
treatment
follow
ribavirin
treatment
possibl
ribavirin
might
antivir
effect
recombin
adenovirus
lenaert
naesen
shown
fig
group
receiv
combin
treatment
use
ribavirin
adporcin
ifna
exhibit
significantli
inhibit
fmdv
replic
howev
sequenti
treatment
use
adporcin
ifna
ribavirin
h
respect
fmdv
infect
effect
simultan
treatment
adporcin
ifna
ribavirin
h
p
h
p
fmdv
infect
test
antifmdv
effect
adenovirusmedi
sirna
porcin
ifna
ribavirin
combin
vivo
inject
antivir
agent
suckl
mice
challeng
ld
ld
fmdv
fig
adenoviru
express
sirna
adsirna
porcin
ifna
adporcin
ifna
ribavirin
inhibit
viral
replic
fmdv
suckl
mice
p
log
rank
test
combin
treatment
group
treat
tcid
adporcin
ifna
mg
ribavirin
adporcin
ifna
group
surviv
rate
day
postchalleng
dpc
ld
fmdv
fig
adsirna
adporcin
ifna
combin
group
adsirna
group
tcid
maintain
surviv
dpc
ld
fmdv
fig
addit
adporcin
ifna
group
maintain
surviv
rate
combin
adporcin
ifna
ribavirin
enhanc
surviv
rate
mice
shown
fig
combin
group
sequenti
treatment
maintain
surviv
rate
combin
group
simultan
treatment
maintain
surviv
rate
dpc
adporcin
ifna
ribavirin
group
surviv
rate
dpc
differ
surviv
rate
sequenti
simultan
treatment
clearli
demonstr
dpc
although
surviv
rate
sequenti
treatment
group
constantli
higher
simultan
treatment
group
data
mean
standard
deviat
sd
three
independ
experi
cytotox
concentr
requir
reduc
cell
viabil
control
valu
b
effect
concentr
requir
reduc
virusinduc
cytopathogen
control
valu
monitor
period
combin
effect
adporcin
ifna
adsirna
ld
fmdv
demonstr
clearli
fig
combin
group
administ
tcid
adporcin
ifna
tcid
adsirna
surviv
rate
dpc
surviv
rate
higher
adporcin
ifna
alon
lower
adsirna
alon
howev
combin
group
tcid
adporcin
ifna
tcid
adsirna
surviv
rate
higher
group
treat
sole
adporcin
ifna
adsirna
dpc
sever
antivir
agent
fmdv
chemic
compound
ifn
sirna
propos
altern
method
fmd
prevent
nettleton
et
al
chinsangaram
et
al
chen
et
al
antivir
agent
differ
mechan
viru
inhibit
ribavirin
mutagen
nucleosid
analogu
convert
triphosph
form
cellular
enzym
recent
lethal
mutagenesi
fmdv
ribavirin
analyz
molecular
basi
ehrenfeld
et
al
peral
et
al
studi
report
ribavirin
lead
lethal
mutagenesi
acceler
occurr
aurich
mutant
cloud
earli
replic
stage
increas
viral
mutat
rate
guanidinehcl
block
atpas
activ
nonstructur
protein
protein
involv
polioviru
replic
saunder
et
al
type
ifn
ifna
ifnb
lead
express
gene
antivir
activ
der
et
al
research
report
treatment
ifna
inhibit
fmdv
cell
process
involv
ifn
abstimul
gene
isg
oligoadenyl
synthetas
oa
doublestrand
rnadepend
protein
kinas
pkr
chinsangaram
et
al
chinsangaram
et
al
gene
fig
enhanc
surviv
rate
fmdv
challeng
singl
combin
adporcin
ifna
adsirna
ribavirin
suckl
mice
suckl
mice
receiv
intraperiton
inject
tcid
adporcin
ifna
adsirna
mg
ribavirin
h
h
fmdv
infect
adporcin
ifna
administ
h
fmdv
infect
ribavirin
administ
h
fmdv
infect
except
combin
group
c
combin
group
receiv
mixtur
adporcin
ifna
ribavirin
h
fmdv
infect
combin
group
receiv
tcid
adporcin
ifna
adsirna
b
combin
group
receiv
tcid
adporcin
ifna
adsirna
suckl
mice
challeng
ld
b
ld
c
fmdv
anim
monitor
day
silenc
caus
sirna
sequencespecif
manner
lead
inhibit
viru
replic
group
report
adenoviru
express
three
differ
sirna
target
nonstructur
protein
gene
region
possess
enhanc
broad
antivir
effect
fmdv
kim
et
al
howev
fmdv
possess
resist
mechan
antivir
agent
fmdv
induc
amino
acid
mutat
region
decreas
sensit
ribavirin
fmdv
leader
sequenc
neg
regul
type
ifn
de
lo
santo
et
al
ferrerorta
et
al
sierra
et
al
wang
et
al
amino
acid
substitut
nonstructur
protein
associ
resist
guanidinehcl
fmdv
belsham
normann
pfister
wimmer
saunder
et
al
addit
sirna
lose
effect
due
escap
mutant
viru
sabariego
et
al
therefor
anticip
combin
treatment
use
antivir
agent
differ
inhibit
mechan
would
effect
circumv
fmdv
resist
combin
antivir
therapi
becom
standard
human
diseas
virus
exampl
human
immunodefici
viru
human
hepat
c
viru
bhagani
reason
compar
antivir
effect
ribavirin
guanidinehcl
adporcin
ifna
adsirna
select
effect
inhibitor
tabl
current
studi
cc
ec
express
use
concentr
unit
measur
chemic
compound
titer
unit
measur
recombin
adenoviru
particular
inhibit
effect
fmdv
discov
first
time
studi
ec
adporcin
ifna
adsirna
measur
tcid
titer
howev
adsirna
led
higher
cytotox
adporcin
ifna
though
also
demonstr
excel
inhibit
effect
predict
adsirna
sirna
promot
induc
mrna
express
ifnb
doublestrand
rnadepend
pkr
oa
cell
addit
rna
interfer
kim
et
al
next
test
combin
effect
antivir
agent
differ
inhibit
mechan
fig
combin
ribavirin
caus
advers
effect
suggest
ribavirin
nucleosid
analog
creat
mutual
metabol
interfer
moreov
recent
report
demonstr
combin
ribavirin
nucleosid
polymeras
inhibitor
result
antagonist
effect
thibaut
et
al
combin
adporcin
ifna
demonstr
much
enhanc
antivir
effect
individu
adporcin
ifna
treatment
reason
adporcin
ifna
combin
addit
inhibit
effect
clear
howev
suggest
might
advers
effect
adenovir
infect
ifn
express
knowledg
first
report
demonstr
combin
ribavirin
porcin
ifna
enhanc
inhibit
effect
fmdv
furthermor
combin
sirna
type
ifn
appli
inhibit
fmdv
previou
studi
report
induct
type
ifn
enhanc
antivir
effect
sirna
human
hepat
b
viru
han
et
al
addit
suggest
adenoviru
express
sirna
promot
activ
gene
relat
type
ifn
enhanc
antivir
effect
kim
et
al
therefor
suggest
current
studi
sirna
type
ifn
interfer
respect
effect
combin
may
potenti
antivir
strategi
combin
tcid
adporcin
ifna
ribavirin
except
high
concentr
lm
ribavirin
lead
enhanc
antivir
effect
wherea
singl
adenoviru
treatment
fig
reason
might
combin
highdos
recombin
adenoviru
ribavirin
combin
ribavirin
human
ifna
protein
common
treatment
method
human
hepat
c
bhagani
therefor
suggest
ribavirin
might
interfer
express
porcin
ifna
recombin
adenoviru
part
ribavirin
might
inhibit
adenoviru
previou
studi
report
ribavirin
antivir
effect
adenovirus
lenaert
naesen
howev
mechan
ribavirin
adenoviru
antivir
effect
recombin
adenoviru
clear
sever
mechan
propos
explain
antivir
activ
due
possibl
compar
simultan
inocul
adporcin
ifna
ribavirin
sequenti
inocul
ribavirin
treatment
follow
adsorpt
adporcin
ifna
fig
sequenti
inocul
adporcin
ifna
ribavirin
h
respect
fmdv
infect
effect
simultan
inocul
result
consist
result
peral
et
al
peral
et
al
sequenti
treatment
ribavirin
guanidinehcl
effect
simultan
combin
treatment
therefor
carri
sequenti
simultan
inject
adporcin
ifna
ribavirin
suckl
mice
expand
examin
anim
fig
effect
antivir
agent
combin
also
demonstr
anim
experi
fig
demonstr
mixtur
adporcin
ifna
adsirna
ribavirin
posit
effect
fmdv
inhibit
effect
antivir
interfer
vivo
surviv
rate
adsirna
higher
adporcin
ifna
titer
ld
ld
although
select
index
adporcin
ifna
cell
higher
adsirna
tabl
one
possibl
reason
inhibit
effect
multipl
sirna
higher
porcin
ifna
anoth
possibl
reason
inhibit
effect
adporcin
ifna
enhanc
stimul
ifn
pathwayrel
gene
porcin
kidney
cell
chinsangaram
et
al
chinsangaram
et
al
gene
stimul
might
taken
place
suckl
mice
model
lack
ifn
respons
ryman
et
al
surviv
rate
combin
group
treat
adporcin
ifna
adsirna
lower
treat
adsirna
alon
combin
group
treat
mixtur
singledos
adporcin
ifna
adsirna
higher
singledos
adsirna
possibl
explan
result
could
antivir
effect
proport
adenoviru
titer
surviv
rate
adsirnatr
group
higher
group
treat
adporcin
ifna
titer
anticip
combin
treatment
use
adporcin
ifna
adsirna
ribavirin
would
advantag
fmdv
control
first
advantag
combin
treatment
could
lead
rapid
effect
inhibit
fmdv
antivir
agent
differ
activ
time
investig
quickli
antivir
effect
adporcin
ifna
adsirna
ribavirin
induc
cell
fig
expect
adsirna
adporcin
ifna
especi
adsirna
greater
advantag
ribavirin
addit
adsirna
adporcin
ifna
could
induc
rapid
inhibit
appli
emerg
situat
second
combin
treatment
could
maintain
inhibit
effect
longer
period
combin
antivir
agent
could
advantag
circumv
fmdv
resist
antivir
agent
might
vari
halflif
anim
furthermor
adporcin
ifna
stimul
gene
relat
antivir
effect
time
progress
treatment
direct
effect
porcin
ifna
protein
chinsangaram
et
al
third
suggest
combin
reduc
quantiti
singl
agent
use
inhibit
fmdv
therefor
propos
combin
adporcin
ifna
ribavirin
adporcin
ifna
adsirna
could
effect
use
emerg
combin
agent
vaccin
order
prevent
spread
fmdv
could
promis
method
agent
could
start
take
effect
within
h
could
maintain
antivir
effect
format
immun
vaccin
studi
natur
host
would
provid
conclus
evid
conclus
compar
promis
antivir
agent
effect
combin
agent
inhibit
fmdv
vitro
vivo
data
report
studi
may
use
develop
effect
longlast
inhibit
fmdv
suggest
combin
propos
studi
adsirna
adporcin
ifna
ribavirin
adporcin
ifna
may
advantag
inhibit
fmdv
differ
mechan
activ
time
studi
necessari
test
enhanc
antivir
effect
natur
host
swine
cattl
goat
fmdv
strain
combin
ratio
inject
dose
could
determin
natur
host
